top of page
Writer's pictureSweetSpot Team

The Impact of GLP-1 Medications on Insulin Pump Users: Key Considerations

Updated: Dec 4

a women checking blood sugar on a cgm

In recent years, glucagon-like peptide-1 (GLP-1) medications, such as Ozempic and Wegovy, have revolutionized diabetes care and weight management. Their unique ability to regulate blood sugar, enhance weight loss, and stabilize post-meal glucose levels has made them a cornerstone of modern diabetes therapy. However, as their use becomes increasingly widespread, it is essential for diabetes professionals to understand how these medications interact with insulin pump therapy. For pump users, GLP-1 medications introduce specific challenges and opportunities, making close monitoring and regular diabetes device data reviews more critical than ever. Without a thoughtful approach to integrating GLP-1s, insulin pump users may face risks such as hypoglycemia, inappropriate insulin dosing, or adverse side effects, underscoring the importance of expert oversight.


This blog will explore the benefits and challenges of integrating GLP-1 medications with insulin pump therapy, provide practical recommendations for providers, and highlight tools for effective monitoring.


What Are GLP-1s and Why Are They Prescribed for Diabetes? 


GLP-1 agonists mimic a natural hormone that regulates blood sugar and appetite. They work by:  

  1. Stimulating Insulin Release: Increasing insulin production to lower blood sugar. 

  2. Reducing Glucagon Production: Lowering glucagon levels, which can raise blood sugar. 

  3. Slowing Digestion: Reducing appetite and promoting weight loss. 

 

The GLP-1 medications that are available in the U.S. include:  

  • Exenatide (Byetta®) 

  • Dulaglutide (Trulicity®) 

  • Exenatide extended release (Bydureon®) 

  • Liraglutide (Victoza®) 

  • Lixisenatide (Adlyxin®) 

  • Semaglutide injection (Ozempic®) 

  • Semaglutide tablets (Rybelsus®) 

 

Potential Benefits of GLP-1s for Insulin Pump Users 

GLP-1 receptor agonists offer a promising treatment option for insulin pump users with Type 2 diabetes. These medications can provide several significant benefits, such as: 

  • Reducing Insulin Requirements: By slowing gastric emptying and improving insulin sensitivity, these medications help stabilize blood sugar, potentially reducing the need for both basal and bolus insulin. 

  • Improving Weight Management: Weight reduction enhances insulin sensitivity, contributing to improved blood sugar control and reduced insulin needs. 

  • Stabilizing Post-Meal Glucose Levels: Slower digestion prevents rapid spikes in blood sugar, enabling smaller, more predictable mealtime boluses. 

By addressing these key areas, GLP-1s can significantly improve the overall quality of life for insulin pump users. They support better blood glucose control, reduce the risk of weight-related complications, and lead to a more manageable diabetes routine, ultimately helping patients feel more confident and in control of their health. 

Risks and Challenges: Why Close Monitoring is Crucial 

While GLP-1 receptor agonists offer numerous benefits for people with Type 2 diabetes, it's important to be aware of the potential risks and challenges. 

Risk of Hypoglycemia 

One of the primary concerns with GLP-1 therapy is the increased risk of hypoglycemia, particularly when combined with insulin therapy. GLP-1s can significantly reduce insulin needs, leading to potential hypoglycemia if insulin doses are not adjusted accordingly. 

Adjusting Insulin Settings 

As the body adapts to GLP-1 therapy, a person with diabetes may need to make significant adjustments to their insulin pump settings. These adjustments can require important daily changes to their diabetes regimen, which may be challenging for those who rely on a consistent routine. Adjustments may include: 

  • Basal Rates: Lower basal rates may be necessary to avoid hypoglycemia, especially during the initial adjustment period. 

  • Bolus Calculations: Mealtime boluses may need to be reduced due to the slower gastric emptying caused by GLP-1s. 

  • Insulin-to-Carb Ratios: The insulin-to-carb ratio may need to be adjusted to account for the changes in insulin sensitivity and glucose absorption. 

Gastrointestinal Side Effects 

GLP-1s can cause gastrointestinal side effects such as nausea, vomiting, and diarrhea. These side effects can impact appetite, nutrient absorption, and insulin dosing. It's important to monitor these symptoms and adjust a patient's meal plan and insulin doses as needed. 

Access and Affordability 

Some GLP-1 medications may lack insurance coverage or require prior authorization, and alternative options like compound pharmacies raise potential issues. Compounded GLP-1 agonists offer cost benefits but may involve dosing errors and counterfeit products, raising safety concerns. Unlike FDA-approved medications, compounded drugs face less regulation when it comes to safety and efficacy. According to endocrinologists and obesity medicine specialists, suppliers cannot ensure the safety and quality of these compounded versions of the drug, making them potentially dangerous for patient use, especially without the proper supervision.  

Practical Recommendations for Healthcare Providers 

Successfully incorporating GLP-1 therapy for insulin pump users requires a thoughtful approach and close collaboration with patients. Effective management is particularly important for insulin pump users, as GLP-1s can impact insulin needs, blood glucose stability, and the timing of insulin delivery. To help patients achieve optimal results, providers should consider the following strategies: 

 

  • Start Slow, Go Slow: Begin with a low dose to minimize side effects. 

  • Adjust Insulin Doses Carefully: Reduce doses based on factors like meal timing and physical activity. 

  • Educate on Hypoglycemia: Ensure patients recognize hypoglycemia symptoms, which may differ with GLP-1 therapy. 

  • Employ Regular Data Reviews: Conduct routine reviews of patient data, such as time-in-range and insulin dosing trends, to optimize therapy effectiveness. 

  • Schedule More Check-Ins With Patients: Frequent follow-ups, either in-person or virtually, allow for early identification of side effects.  

Tools for Closely Monitoring GLP-1 Therapy in Insulin Pump Users 

Close monitoring and regular diabetes data reviews are essential for insulin pump users on GLP-1 therapy. Because GLP-1 medications can significantly alter insulin needs, blood sugar levels, and digestive processes, patients may require frequent adjustments to their insulin regimen to avoid hypoglycemia or other complications. Tools like SweetSpot make it easier to manage these changes by providing real-time data and insights, enabling healthcare providers to: 

  • Monitor Patient Progress: Track key metrics such as time-in-range, insulin dosing, and weight trends to understand the patient’s response to therapy. 

  • Identify Potential Issues Early: Detect signs of hypoglycemia, hyperglycemia, or other complications before they escalate, ensuring timely intervention. 

  • Optimize Treatment Plans: Make data-driven adjustments to insulin pump settings and GLP-1 dosage between appointments, supporting consistent glycemic control. 

  • Reduce In-Person Appointments: Utilize remote monitoring capabilities to minimize frequent office visits, particularly valuable during the early stages of GLP-1 therapy. 

SweetSpot’s dedicated clinical team is available to assist with data reviews, provide expert recommendations, and communicate with patients to offer education and support. As GLP-1 therapies gain popularity, SweetSpot offers a comprehensive solution for personalized, monitored patient care—minimizing risks and enhancing outcomes for insulin pump users on GLP-1 medications.


Want to learn more about SweetSpot and how we are revolutionizing diabetes management? Check out our website or shoot us a message at info@sweetspot.health.  


 

SweetSpot is a remote diabetes management platform that supports all major diabetes devices and insulin delivery systems to provide physicians with a single view of their patients’ data. SweetSpot's intelligent algorithm identifies the most optimal CPT codes for both remote and in-person diabetes management, and a dedicated team of Certified Diabetes Care & Education Specialists provide ongoing support.  


As a company founded and powered by physicians and diabetes care providers, we place a strong emphasis on ensuring that there are no obstacles to getting started with SweetSpot. That’s why SweetSpot is easy to set up and designed to seamlessly integrate into your existing workflows and comes with no setup costs or subscription fees. 

0 comments
bottom of page